Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Inizio celebrates six finalist honors at the 2025 PM360 Trailblazer Awards

September 24, 2025 |  

Inizio has been named a finalist in six categories at the 2025 PM360 Trailblazer Awards, recognizing its teams’ excellence in AI, data analytics, education, patient engagement, and industry partnership across Inizio Evoke, Inizio Engage, and Inizio Medical.

PM360AwardsInizio

We’re proud to announce that our teams across Inizio Evoke, Inizio Engage, and Inizio Medical have been named finalists in six prestigious categories at the 2025 PM360 Trailblazer Awards, which recognize excellence and innovation in healthcare marketing. 

The PM360 Trailblazer Awards honor the most impactful initiatives, strategies, and companies driving change in the healthcare industry across eight core categories. This year, our recognition spans multiple disciplines – highlighting our expertise in artificial intelligence (AI), data analytics, patient and healthcare professional (HCP) education, and persistence/adherence programs, as well as our standing as a top industry partner. 

Our 2025 PM360 trailblazer award finalist categories 

Driving innovation across healthcare marketing 

These finalist recognitions demonstrate how our connected capabilities empower life sciences organizations to achieve greater patient engagement, educational impact, and data-driven decision-making. Our work leverages cutting-edge AI and analytics, compelling creative strategies, and deep scientific expertise to deliver measurable results for our clients and ultimately improve healthcare outcomes. 

Looking ahead 

We are honored to be recognized alongside such inspiring organizations and partners. These six finalist nominations reflect the passion, creativity, and expertise of our teams across Inizio. 

Good luck to all of this year’s finalists – we look forward to celebrating the incredible work shaping the future of healthcare marketing. Stay tuned for the results and follow our updates on LinkedIn. 

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

The challenges of conducting effective pharmaceutical market research in emerging markets

Published in Quirk's Marketing Research Review, April 2016, By Marc Yates, Director of Emerging Markets

Blog: Viewing facility research, re-imagined

As technology has evolved, so too has the world of qualitative research

Video: Immuno-oncology therapies

Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high...

Event: EULAR Annual European Congress of Rheumatology 2016

We are delighted to be attending the EULAR Annual European Congress of Rheumatology in June. Representing Research Partnership is Business Development Manager, Fara Mboge. He will be on hand to...

Forever Angels achievements and development plan for 2016

Research Partnership is proud to support Forever Angels in their mission of caring for and improving the lives of orphans and abandoned infants in Tanzania

The Opportunity for Women’s Health in Emerging Markets

Published in eyeforpharma April 2016 by Rachel Howard

Video: Storytelling in healthcare market research

Within the pharmaceutical industry, there is an increasing need for market research teams to share the insights with their key internal stakeholders, from marketing and brand managers to sales reps...

Promotions and new appointments across our global offices

Research Partnership is delighted to announce promotions and new starters in the UK and further appointments in the US and Singapore offices

Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy...

Webcast: Understanding the Chronic Disease Patient Journey in Emerging Markets

In emerging markets where primary care systems do not exist, the patient is the only constant in the journey